SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Eli Lilly's biotechnology center in California
Pain
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program
Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly said that results were not sufficient for advancement of the Asahi Kasei–partnered asset.
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary digital collage art. Modern trippy design. Hands holding fork and spoon
Earnings
Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes
Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology.
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept art showing a money icon and human hands
IPO
Evommune Joins IPO Class With Planned $160M Raise for Immuno Pipeline
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Ladder of Success
C-suite
An Early-Career Stand Proved This Young Biotech Exec Had What It Takes
Ensho Therapeutics CEO Neena Bitritto-Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the one between Eisai and Biogen that led to new Alzheimer’s drugs Aduhelm and Leqembi.
October 31, 2025
 · 
6 min read
 · 
Annalee Armstrong
Businessman keeps the seesaw balanced
Earnings
Lilly Walks Pricing Tightrope With Upcoming Weight Loss Pill Orforglipron
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs to pay for the next generation of obesity medicines to come after that.
October 30, 2025
 · 
4 min read
 · 
Annalee Armstrong
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Earnings
Merck Vaccine Sales Drop as US Declines Strike Another Pharma
While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.
October 30, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Earnings
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives on the company’s investor call faced questions about a sluggish uptake for schizophrenia drug Cobenfy as well as a highly anticipated Alzheimer’s psychosis readout for the product.
October 30, 2025
 · 
3 min read
 · 
Heather McKenzie
Woman, physician, doctor with magnifying glass standing on ladder. Square composition. EPS10.
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?
October 30, 2025
 · 
2 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH ELEMENT
Innovation, Resilience, and the Future of Global Manufacturing
In this episode presented by Element Materials Technology, BioSpace’s head of insights discusses how China, historically focused on manufacturing, is increasingly becoming an innovation leader, particularly in pharmaceuticals, with guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney. Ultimately, balanced strategies involve domestic capacity investments coupled with global collaboration.
October 30, 2025
 · 
1 min read
 · 
BioSpace Insights
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS